-
Are there any reliable predictors of unreported alcohol consumption in MAFLD patients? J. Hepatol. (IF 25.083) Pub Date : 2022-06-25 Agostino Colli, Mirella Fraquelli, Giovanni Casazza
Abstract not available
-
Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis J. Hepatol. (IF 25.083) Pub Date : 2022-06-25 Lucy Gracen, Kelly L. Hayward, Katharine M. Irvine, Patricia C. Valery, Elizabeth E. Powell
Abstract not available
-
NUDT1 promotes the accumulation and longevity of CD103+ TRM cells in primary biliary cholangitis J. Hepatol. (IF 25.083) Pub Date : 2022-06-23 Bingyuan Huang, Zhuwan Lyu, Qiwei Qian, Yong Chen, Jun Zhang, Bo Li, Yikang Li, Jubo Liang, Qiaoyan Liu, You Li, Ruiling Chen, Min Lian, Xiao Xiao, Qi Miao, Qixia Wang, Jingyuan Fang, Zhexiong Lian, Yanmei Li, Xiong Ma
-
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation J. Hepatol. (IF 25.083) Pub Date : 2022-06-22 Ibone Labiano, Aloña Agirre-Lizaso, Paula Olaizola, Anne Echebarria, Maider Huici-Izagirre, Irene Olaizola, Aitor Esparza-Baquer, Omar Sharif, Elizabeth Hijona, Piotr Milkiewicz, Malgorzata Milkiewicz, Francisco González-Romero, Patricia Aspichueta, Maria J. Monte, Jose J.G. Marin, Mihael Vucur, Tom Luedde, Marco Marzioni, Maria J. Perugorria.
-
EASL International Recognition Award Recipient 2022: Prof. Patrick S. Kamath J. Hepatol. (IF 25.083) Pub Date : 2022-06-22 Pere Ginès
Abstract not available
-
EASL International Recognition Awardee 2022: Dr. Pere Ginès J. Hepatol. (IF 25.083) Pub Date : 2022-06-22 Paolo Angeli
Abstract not available
-
EASL Recognition Award Recipient 2022: Dr Sophie Lotersztajn J. Hepatol. (IF 25.083) Pub Date : 2022-06-22 Ariane Mallat
Abstract not available
-
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits J. Hepatol. (IF 25.083) Pub Date : 2022-06-22 Moritz Peiseler, Robert Schwabe, Jochen Hampe, Paul Kubes, Mathias Heikenwälder, Frank Tacke
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and emerging as the leading cause of liver cirrhosis, liver transplantation and hepatocellular carcinoma (HCC). NAFLD is a metabolic disease and considered the hepatic manifestation of the metabolic syndrome; however, during the evolution of NAFLD from steatosis to nonalcoholic steatohepatitis (NASH), to more advanced
-
EASL innovation award recipient 2022: Prof. Martin Rössle J. Hepatol. (IF 25.083) Pub Date : 2022-06-22 Robert Thimme
Abstract not available
-
BULEVIRTIDE WITH OR WITHOUT PEGIFNα FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES J. Hepatol. (IF 25.083) Pub Date : 2022-06-22 Pietro Lampertico, Dominique Roulot, Heiner Wedemeyer
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, displaying a superior risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC). Pegylated-Interferon α (pegIFNα), the only off-label therapeutic option that has been available for the last 30 years, has suboptimal response rates and it is poorly tolerated. Among the new treatment strategies under clinical evaluation
-
Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer J. Hepatol. (IF 25.083) Pub Date : 2022-06-21 Dan Høgdall, Colm J. O’Rourke, Finn O. Larsen, Shahryar Zarforoushan, Troels D. Christensen, Awaisa Ghazal, Mogens K. Boisen, Patricia Muñoz-Garrido, Julia S. Johansen, Jesper B. Andersen
-
Thriving in turbulent times: EASL reflects on 2021, looking to 2022 and beyond J. Hepatol. (IF 25.083) Pub Date : 2022-06-21 Thomas Berg, Aleksander Krag
Abstract not available
-
Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. J. Hepatol. (IF 25.083) Pub Date : 2022-06-21 Tim Hendrikx, Florentina Porsch, Máté G. Kiss, Dragana Rajcic, Nikolina Papac-Miličević, Constanze Hoebinger, Laura Göderle, Anastasiya Hladik, Lisa E. Shaw, Hauke Horstmann, Sylvia Knapp, Sophia Derdak, Martin Bilban, Lena Heintz, Marcin Krawczyk, Rafael Paternostro, Michael Trauner, Matthias Farlik, Christoph J. Binder
-
EASL Clinical Practice Guidelines on sclerosing cholangitis J. Hepatol. (IF 25.083) Pub Date : 2022-06-21
Management of primary or secondary sclerosing cholangitis is challenging. These Clinical Practice Guidelines have been developed to provide practical guidance on debated topics including diagnostic methods, prognostic assessment, early detection of complications, optimal care pathways and therapeutic (pharmacological, endoscopic or surgical) options both in adults and children.
-
Signed, SEALed, detected I’m your patient with advanced fibrosis or cirrhosis! J. Hepatol. (IF 25.083) Pub Date : 2022-06-20 Peter Jepsen, Helen Reeves
Abstract not available
-
Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target J. Hepatol. (IF 25.083) Pub Date : 2022-06-20 Giorgia Alvisi, Alberto Termanini, Cristiana Soldani, Federica Portale, Roberta Carriero, Karolina Pilipow, Guido Costa, Michela Polidoro, Barbara Franceschini, Ines Malenica, Simone Puccio, Veronica Lise, Giovanni Galletti, Veronica Zanon, Federico Simone Colombo, Gabriele De Simone, Michele Tufano, Alessio Aghemo, Ana Lleo
-
HBsAg Seroclearance and Reduction in Late Recurrence of HBV-related HCC: Causality or Co-existence? J. Hepatol. (IF 25.083) Pub Date : 2022-06-19 Yong-Kang Diao, Qing-Yu Kong, Tian Yang
Abstract not available
-
Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al. J. Hepatol. (IF 25.083) Pub Date : 2022-06-19 Aurélie Beaufrère, Valérie Vilgrain, Valérie Paradis
Abstract not available
-
EASL Clinical Practice Guidelines on the management of cystic liver diseases J. Hepatol. (IF 25.083) Pub Date : 2022-06-18
The advent of enhanced radiological imaging techniques has facilitated the diagnosis of cystic liver lesions. Concomitantly, the evidence base supporting the management of these diseases has matured over the last decades. As a result, comprehensive clinical guidance on the subject matter is warranted. These Clinical Practice Guidelines cover the diagnosis and management of hepatic cysts, mucinous cystic
-
Corrigendum to ‘Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy’ [J Hepatol 76 (2022) 1330-1347] J. Hepatol. (IF 25.083) Pub Date : 2022-06-17 Andrea Schlegel, Robert J. Porte, Philipp Dutkowski
Abstract not available
-
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy J. Hepatol. (IF 25.083) Pub Date : 2022-06-17
The EASL Clinical Practice Guidelines (CPGs) on the management of hepatic encephalopathy (HE) present evidence-based answers to a set of relevant questions (where possible, formulated in PICO [patient/population, intervention, comparison and outcomes] format) on the definition, diagnosis, differential diagnosis and treatment of HE. The document does not cover the pathophysiology of HE and does not
-
Letter to the editor - A peditatric hepatologists’ perspective J. Hepatol. (IF 25.083) Pub Date : 2022-06-15 Eberhard Lurz, Dominic Lenz, Philip Bufler, Alexander Fichtner, Stephan Henning, Martin Jankofsky, Simone Kathemann, Michael Melter, Jun Oh, Eva Doreen Pfister, Ekkehard Sturm, Birgit Knoppke, Elke Lainka
Abstract not available
-
2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: a too early endpoint? J. Hepatol. (IF 25.083) Pub Date : 2022-06-16 Renato Medas, Rodrigo Liberal, Hélder Cardoso, Guilherme Macedo
Abstract not available
-
Stigma and care avoidance in people with unhealthy alcohol use: a call for research and action J. Hepatol. (IF 25.083) Pub Date : 2022-06-15 Patrizia Carrieri, Tangui Barré, Morgane Bureau, Fabienne Marcellin, Abbas Mourad
Abstract not available
-
SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis J. Hepatol. (IF 25.083) Pub Date : 2022-06-15 Nadia Bresciani, Hadrien Demagny, Vera Lemos, Francesca Pontanari, Xiaoxu Li, Yu Sun, Hao Li, Alessia Perino, Johan Auwerx, Kristina Schoonjans
-
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy J. Hepatol. (IF 25.083) Pub Date : 2022-06-15 Man-Fung Yuen, Jeong Heo, Hiromitsu Kumada, Fumitaka Suzuki, Yoshiyuki Suzuki, Qing Xie, Jidong Jia, Yoshiyasu Karino, Jinlin Hou, Kazuaki Chayama, Michio Imamura, Judy Y. Lao-Tan, Seng Gee Lim, Yasuhito Tanaka, Wen Xie, Jung-Hwan Yoon, Zhongping Duan, Masayuki Kurosaki, Dickens Theodore
-
Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy J. Hepatol. (IF 25.083) Pub Date : 2022-06-15 Amaia Lujambio, Pablo Sarobe
Abstract not available
-
Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen+ infection J. Hepatol. (IF 25.083) Pub Date : 2022-06-15 Ruben C. Hoogeveen, Suzan Dijkstra, Lea M. Bartsch, Hannah Drescher, Jasneet Aneja, Maxwell P. Robidoux, James A. Cheney, Jörg Timm, Adam Gehring, Paulo Sergio Fonseca de Sousa, Lya Ximenez, Luis Baiao Peliganga, Anita Pitts, Fiona Evans Blackburn, André Boonstra, Arthur Y. Kim, Lia L. Lewis-Ximenez, Georg M. Lauer
-
-
Register now for the EASL NAFLD Summit, 15-17 September, in Dublin (Ireland) J. Hepatol. (IF 25.083) Pub Date : 2022-06-15
Abstract not available
-
Visit EASL Campus & browse through a large catalogue of resources on hepatology & liver-related research J. Hepatol. (IF 25.083) Pub Date : 2022-06-15
Abstract not available
-
EASL Studio is streaming live every week and bringing you hepatology news, from every angle J. Hepatol. (IF 25.083) Pub Date : 2022-06-15
Abstract not available
-
Discover all EASL activities and resources for young investigators in hepatology J. Hepatol. (IF 25.083) Pub Date : 2022-06-15
Abstract not available
-
-
From the Editor’s Desk... J. Hepatol. (IF 25.083) Pub Date : 2022-06-15 Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli
Abstract not available
-
-
External validation of a genetic risk score that predicts development of alcohol-related cirrhosis J. Hepatol. (IF 25.083) Pub Date : 2022-06-14 Stine Johansen, Maja Thiele, Helene Baek Juel, Torben Hansen, Aleksander Krag
Abstract not available
-
Challenges and issues in bivariate endpoints in study designs of translational medicine J. Hepatol. (IF 25.083) Pub Date : 2022-06-13 Qian Zhou
Abstract not available
-
Interventional treatment of hepatocellular carcinoma J. Hepatol. (IF 25.083) Pub Date : 2022-06-12 Riad Salem, Lambros Tselikas, Thierry De Baere
Abstract not available
-
Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential? J. Hepatol. (IF 25.083) Pub Date : 2022-06-11 William Alazawi
Abstract not available
-
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection J. Hepatol. (IF 25.083) Pub Date : 2022-06-11 Mark S. Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T. Nguyen, Eugene R. Schiff, Hie-Won L. Hann, Douglas T. Dieterich, Ronald G. Nahass, James S. Park, Sing Chan, Steven-Huy B. Han, Edward J. Gane, Michael Bennett, Katia Alves, Marc Evanchik, Ran Yan, Qi Huang, Uri Lopatin, Man-Fung Yuen
-
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations J. Hepatol. (IF 25.083) Pub Date : 2022-06-09 Yongquan Tang, Yan Chen, Hai-Ning Chen
Abstract not available
-
Porto-sinusoidal vascular disorder J. Hepatol. (IF 25.083) Pub Date : 2022-06-09 Andrea De Gottardi, Christine Sempoux, Annalisa Berzigotti
It is well established that portal hypertension (PH) can occur in the absence of cirrhosis, as reported in patients with immune disorders, infections and thrombophilia. However, similar histological abnormalities affecting primarly the hepatic sinusoidal and the (peri)portal vasculature have also been observed in patients without PH. Thus, the term porto-sinusoidal vascular disorder (PSVD) has been
-
Validation of the Chronic Liver Disease (CLivD) score J. Hepatol. (IF 25.083) Pub Date : 2022-06-09 Fredrik Åberg, Panu K. Luukkonen, Martti Färkkilä
Abstract not available
-
On coagulation in advanced chronic liver disease and the origin of freshwater eels J. Hepatol. (IF 25.083) Pub Date : 2022-06-07 Mattias Mandorfer, Bernhard Scheiner, Ton Lisman
Abstract not available
-
LIVER STIFFNESS, BUT NOT FATTY LIVER DISEASE, IS ASSOCIATED WITH ATRIAL FIBRILLATION: THE ROTTERDAM STUDY J. Hepatol. (IF 25.083) Pub Date : 2022-06-07 Laurens A. van Kleef, Zuolin Lu, M. Arfan Ikram, Natasja M.S. de Groot, Maryam Kavousi, Robert J. de Knegt
-
Surgical treatment of intrahepatic cholangiocarcinoma J. Hepatol. (IF 25.083) Pub Date : 2022-06-05 Annabel K. Gravely, Eric Vibert, Gonzalo Sapisochin
Abstract not available
-
EASL Clinical Practice Guidelines on haemochromatosis J. Hepatol. (IF 25.083) Pub Date : 2022-06-01
Haemochromatosis is characterised by elevated transferrin saturation (TSAT) and progressive iron loading that mainly affects the liver. Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropathy and other complications. In patients homozygous for p.Cys282Tyr in HFE, provisional iron overload based on serum iron parameters (TSAT >45% and ferritin
-
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis J. Hepatol. (IF 25.083) Pub Date : 2022-05-31 Càndid Villanueva, Ferran Torres, Shiv Kumar Sarin, Hasnain Ali Shah, Dhiraj Tripathi, Anna Brujats, Susana G. Rodrigues, Ankit Bhardwaj, Zahid Azam, Peter C. Hayes, Ankur Jindal, Shahab Abid, Edilmar Alvarado, Jaume Bosch
-
Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread J. Hepatol. (IF 25.083) Pub Date : 2022-05-28 Zhenfeng Zhang, Yi Ni, Florian A. Lempp, Lisa Walter, Pascal Mutz, Ralf Bartenschlager, Stephan Urban
-
Mechanisms of CD8+ T cell failure in chronic hepatitis E virus infection J. Hepatol. (IF 25.083) Pub Date : 2022-05-28 Janine Kemming, Swantje Gundlach, Marcus Panning, Daniela Huzly, Jiabin Huang, Marc Lütgehetmann, Sven Pischke, Julian Schulze zur Wiesch, Florian Emmerich, Sian Llewellyn-Lacey, David A. Price, Yakup Tanriver, Klaus Warnatz, Tobias Boettler, Robert Thimme, Maike Hofmann, Nicole Fischer, Christoph Neumann-Haefelin
-
Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma J. Hepatol. (IF 25.083) Pub Date : 2022-05-27 Laura Molina, Junjie Zhu, Eric Trépo, Quentin Bayard, Giuliana Amaddeo
-
Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner J. Hepatol. (IF 25.083) Pub Date : 2022-05-27 June-Young Koh, Min-Seok Rha, Seong Jin Choi, Ha Seok Lee, Ji Won Han, Heejin Nam, Dong-Uk Kim, Jae Geun Lee, Myoung Soo Kim, Jun Yong Park, Su-Hyung Park, Dong Jin Joo, Eui-Cheol Shin
-
The recent outbreak of acute severe hepatitis in children of unknown origin J. Hepatol. (IF 25.083) Pub Date : 2022-05-27 Guangting Zeng, Jing Huang
Abstract not available
-
Impact of HBsAg seroclearance on late recurrence of hepatitis B virus–related hepatocellular carcinoma after surgical resection J. Hepatol. (IF 25.083) Pub Date : 2022-05-26 Sun Yoo, Ji Yoon Kim, Young-Suk Lim, Seungbong Han, Jonggi Choi
-
Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission J. Hepatol. (IF 25.083) Pub Date : 2022-05-26 Tatyana Kushner, Maya Djerboua, Mia J. Biondi, Jordan J. Feld, Norah Terrault, Jennifer A. Flemming
-
Rat Hepatitis E virus is a potential zoonotic pathogen to humans J. Hepatol. (IF 25.083) Pub Date : 2022-05-25 Zhongyao Qian, Xianhui Hao, Yueping Xia, Wenhai Yu, Fen Huang
Abstract not available
-
Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis J. Hepatol. (IF 25.083) Pub Date : 2022-05-25 Sophia Pouriki, Theodoros Alexopoulos, Larisa Vasilieva, Georgia Vrioni, Alexandra Alexopoulou
Abstract not available
-
Lack of Hepatic Autophagy Promotes Severity of Liver Injury but Not Steatosis J. Hepatol. (IF 25.083) Pub Date : 2022-05-25 Wen-Xing Ding, Hong-Min Ni, Satoshi Waguri, Masaaki Komatsu
Abstract not available
-
Chronic hepatitis E: advancing research and patient care J. Hepatol. (IF 25.083) Pub Date : 2022-05-21 Zhongren Ma, Robert A. de Man, Nassim Kamar, Qiuwei Pan
The hepatitis E virus (HEV) was initially thought to exclusively cause acute hepatitis. However, the first diagnosis of chronic hepatitis E in transplant recipients in 2008 profoundly changed our understanding of this pathogen. We have now begun to understand that specific HEV genotypes can cause chronic infection in certain immunocompromised populations. Over the past decade, dedicated clinical and